

CSD/BM/SE/2026-27

Date: July, 08, 2026

**To**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 530239**

**Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: Revised Outcome of the Meeting of Board of Directors**

.....

Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended and other applicable provisions of law, this is to inform that the Board of Directors of the Company, at its meeting held today i.e. July 08, 2026, has inter-alia considered and approved the following:

**1. Allotment of 1,85,70,133 Equity Shares of the Company on preferential basis upon conversion 1,85,70,133 fully paid warrants**

The Board of Directors has approved Conversion of 1,85,70,133 fully paid warrants and issued & allotted 1,85,70,133 (One Crore Eighty-Five Lakhs Seventy Thousand One Hundred thirty- three only) Equity Shares of Rs.1/- each to the following Non-Promoter Persons/ Entities at an issue price of Rs. 134/- per share on preferential basis in accordance with SEBI (Issue of Capital and Requirements) Regulations, 2018.

<b>Sl. No.</b>	<b>Non-promoter persons/entities</b>	<b>No. of Equity shares allotted</b>
1.	TEJAS TRIVEDI	37,31,343
2.	KETAN CHHOTALAL SHETH	20,00,000
3.	ITI HOLDINGS AND INVESTMENT PRIVATE LIMITED	18,65,670
4.	ARUN NAHAR	15,00,000
5.	JAGDISH N MASTER	15,00,000
6.	NILESH KISHORE SHAH	12,00,000
7.	NIMESH ARVIND DOSHI	11,94,100
8.	ORACULAR ADVISORY PRIVATE LIMITED	11,25,000

**Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

9.	ATMAN INVESTMENTS PRIVATE LIMITED	10,00,000
10.	ZAPFIN TEKNOLOGIES PRIVATE LIMITED (Formerly, Trishakti Power Holdings Private Limited)	10,00,000
11.	TIKRI PARTNERS LLP	7,46,260
12.	CAMPBELL ADVERTISING PRIVATE LIMITED	4,47,760
13.	NIMISH CHANDULAL SHAH	3,60,000
14.	SHARAD NANDLAL SHAH	3,00,000
15.	NEHA IYENGAR	3,00,000
16.	SHANTIKUMAR GIRDHARLAL SHAH	1,50,000
17.	CHARU MAHENDRA PARIKH	1,50,000
	<b>Total</b>	<b>1,85,70,133</b>

Further it is informed that the Company has received from the above said allottees 100% consideration amount aggregating to Rs. 248,83,97,822/- in compliance with SEBI (ICDR) Regulations, 2018.

**Consequently, the paid-up equity share capital of the company stands increased to the following:**

<i>Particulars</i>	<i>No. of Equity Shares</i>	<i>Amount in INR</i>
Pre-issue subscribed & paid-up capital	263992553	26,39,92,553/-
<b>Post-issue subscribed &amp; paid-up capital</b>	<b>282562686</b>	<b>28,25,62,686/-</b>

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as **Annexure A**.

## 2. Re-appointment of Independent Director

Based on the recommendation of the Nomination and Remuneration Committee in its meeting held today i.e. 08<sup>th</sup> July, 2026, the Board of Directors has approved the re-appointment of Dr. Vajja Sambasiva Rao (DIN: 09233939) as Non-Executive Independent Director of the Company for a second term of Five (5) years w.e.f. 21<sup>st</sup> January, 2027 to 20<sup>th</sup> January, 2032, subject to approval of the Members of the Company at the ensuing Annual General meeting.

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as **Annexure B**.

## Suven Life Sciences Limited

3. Incorporation of Wholly owned Subsidiary (WOS) In Singapore

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026 is enclosed as revised **Annexure C**

The Board Meeting commenced at 11:50 A.M (IST) and concluded at 12:35 P.M (IST).

This is for your information and records.

Thanking you.

Yours faithfully,

For **Suven Life Sciences Limited**

**K. Sangeetha Laxmi**

Company Secretary and Compliance officer

Encl: as above

**Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)

**ANNEXURE A**

**Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sl. no.	Particulars	Details																																																
a)	Type of securities proposed to be issued (viz. equity shares, convertibles etc.);	Fully paid-up equity shares upon conversion of warrants																																																
b)	Type of issuance (further public offering, rights issue, depository receipts (ADR/ GDR), qualified institutions placement, preferential allotment etc.);	Preferential Allotment in accordance with Chapter V of the SEBI (ICDR) Regulations, 2018 and other applicable law.																																																
c)	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	<b>1,85,70,133</b> Equity Shares of face value of Rs. 1/- each pursuant to conversion of <b>1,85,70,133</b> warrants at an issue price of ₹ 134/- per warrant, for an aggregate consideration of Rs. 248,83,97,822/- to below allottee.																																																
d)	In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):																																																	
	i. number of investors;	17																																																
	ii. names of the investors;	<table border="1"> <thead> <tr> <th>Sl. No</th> <th>Non-Promoter entities/ Persons</th> <th>No. of Equity Shares allotted</th> </tr> </thead> <tbody> <tr><td>1</td><td>TEJAS TRIVEDI</td><td>37,31,343</td></tr> <tr><td>2</td><td>KETAN CHHOTALAL SHETH</td><td>20,00,000</td></tr> <tr><td>3</td><td>ITI HOLDINGS AND INVESTMENT PRIVATE LIMITED</td><td>18,65,670</td></tr> <tr><td>4</td><td>ARUN NAHAR</td><td>15,00,000</td></tr> <tr><td>5</td><td>JAGDISH N MASTER</td><td>15,00,000</td></tr> <tr><td>6</td><td>NILESH KISHORE SHAH</td><td>12,00,000</td></tr> <tr><td>7</td><td>NIMESH ARVIND DOSHI</td><td>11,94,100</td></tr> <tr><td>8</td><td>ORACULAR ADVISORY PRIVATE LIMITED</td><td>11,25,000</td></tr> <tr><td>9</td><td>ATMAN INVESTMENTS PRIVATE LIMITED</td><td>10,00,000</td></tr> <tr><td>10</td><td>ZAPFIN TEKNOLOGIES PRIVATE LIMITED (Formerly, Trishakti Power Holdings Private Limited)</td><td>10,00,000</td></tr> <tr><td>11</td><td>TIKRI PARTNERS LLP</td><td>7,46,260</td></tr> <tr><td>12</td><td>CAMPBELL ADVERTISING PRIVATE LIMITED</td><td>4,47,760</td></tr> <tr><td>13</td><td>NIMISH CHANDULAL SHAH</td><td>3,60,000</td></tr> <tr><td>14</td><td>SHARAD NANDLAL SHAH</td><td>3,00,000</td></tr> <tr><td>15</td><td>NEHA IYENGAR</td><td>3,00,000</td></tr> </tbody> </table>	Sl. No	Non-Promoter entities/ Persons	No. of Equity Shares allotted	1	TEJAS TRIVEDI	37,31,343	2	KETAN CHHOTALAL SHETH	20,00,000	3	ITI HOLDINGS AND INVESTMENT PRIVATE LIMITED	18,65,670	4	ARUN NAHAR	15,00,000	5	JAGDISH N MASTER	15,00,000	6	NILESH KISHORE SHAH	12,00,000	7	NIMESH ARVIND DOSHI	11,94,100	8	ORACULAR ADVISORY PRIVATE LIMITED	11,25,000	9	ATMAN INVESTMENTS PRIVATE LIMITED	10,00,000	10	ZAPFIN TEKNOLOGIES PRIVATE LIMITED (Formerly, Trishakti Power Holdings Private Limited)	10,00,000	11	TIKRI PARTNERS LLP	7,46,260	12	CAMPBELL ADVERTISING PRIVATE LIMITED	4,47,760	13	NIMISH CHANDULAL SHAH	3,60,000	14	SHARAD NANDLAL SHAH	3,00,000	15	NEHA IYENGAR	3,00,000
Sl. No	Non-Promoter entities/ Persons	No. of Equity Shares allotted																																																
1	TEJAS TRIVEDI	37,31,343																																																
2	KETAN CHHOTALAL SHETH	20,00,000																																																
3	ITI HOLDINGS AND INVESTMENT PRIVATE LIMITED	18,65,670																																																
4	ARUN NAHAR	15,00,000																																																
5	JAGDISH N MASTER	15,00,000																																																
6	NILESH KISHORE SHAH	12,00,000																																																
7	NIMESH ARVIND DOSHI	11,94,100																																																
8	ORACULAR ADVISORY PRIVATE LIMITED	11,25,000																																																
9	ATMAN INVESTMENTS PRIVATE LIMITED	10,00,000																																																
10	ZAPFIN TEKNOLOGIES PRIVATE LIMITED (Formerly, Trishakti Power Holdings Private Limited)	10,00,000																																																
11	TIKRI PARTNERS LLP	7,46,260																																																
12	CAMPBELL ADVERTISING PRIVATE LIMITED	4,47,760																																																
13	NIMISH CHANDULAL SHAH	3,60,000																																																
14	SHARAD NANDLAL SHAH	3,00,000																																																
15	NEHA IYENGAR	3,00,000																																																

**Suven Life Sciences Limited**

		16	SHANTIKUMAR GIRDHARLAL SHAH	1,50,000
		17	CHARU MAHENDRA PARIKH	1,50,000
	iii. post allotment of securities - outcome of the subscription	Pursuant to conversion, the issued, subscribed and paid-up equity share capital of the Company stands increased to Rs. 282562686/- consisting of 282562686 fully paid-up equity shares of Rs. 1/- each.		
	iv. issue price/ allotted price (in case of convertibles)	Rs. 134/- per share		
	v. in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Allotment of 18570133 equity shares pursuant to the conversion of warrants at an issue price of Rs. 134/- each (face value of Rs. 1/- each and premium of Rs. 133/- each) upon receipt of 100% consideration amount from above mentioned allottee amounting to Rs. 248,83,97,822/-		
e)	any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not applicable		

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

**ANNEXURE B**

**Disclosure required pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

1)	Name of Director	Dr. Vajja Sambasiva Rao (DIN: 09233939)
2)	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment as Non-Executive Independent Director of the Board
3)	Date of appointment/ <del>cessation</del> and Term of appointment	Re-appointment is effective from January 21, 2027 for a tenure of 5 (five) years subject to the approval of Members in the ensuing Annual General Meeting
4)	Brief profile (in case of appointment)	<p>Dr. Vajja Sambasiva Rao is a Master of Science and Ph. D Chemistry from BITS Pilani and he is an alumnus of BITS, Pilani and the University of Bielefeld, Germany.</p> <p>Dr. Vajja Sambasiva Rao is also an academician; he retired as Vice Chancellor of SRM University-AP on 9th September 2022 and moving onward continued as an Adviser to President and Pro-Chancellor SRM University AP until October 2025. He has joined as Advisor to BITS Pilani Amaravati Campus on 1st Nov 2025 and continues to work in this role. He previously served as the President of NIIT University and Acting Vice-Chancellor and Director at BITS, Pilani. He played a crucial role in the establishment of BITS Pilani, Hyderabad campus in terms of strategy and conception. As a director he comes with vast experience in chemistry, governance and knowledge in project &amp; financial management. He is also a member of Expert Committee of APSCHE for Screening Private Universities from 2026.</p> <p>He has been the recipient of "Demonstrated Excellence in Building an Institution" award from the Chancellor, BITS in 2014. He was honoured in BITSAA Global Meet in 2014 for his contribution to "Making Learning a Wonderful Experience". In 2013, he received "Eminent Educationist Award" by Indo Global Educational Council for his achievements in education and honoured for contribution to excellence in education by Telugu Association of North America (TANA), USA.</p>
5)	Disclosure of relationships between directors (in case of appointment of a director)	Not related to any directors
6)	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively.	Dr. Vajja Sambasiva Rao is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such authority

**Suven Life Sciences Limited**

### Annexure C

#### Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl.No	Particulars	Details
1	Name of the entity, Date & Country of incorporation, etc.	<b>Suven Neurosciences Pte. Ltd.</b> to be incorporated in Singapore.
2	Name of holding company of the incorporated company and relation with the listed entity;	Suven Life Sciences Limited is incorporating the said WOS.
3	Industry to which the entity being incorporated belongs;	Bio-Pharmaceutical, clinical development
4	Brief background about the entity incorporated in terms of products / line of business	Clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for treatment of neurological and other disorders.
5	Brief details of any governmental or regulatory approvals required for the incorporation	Not Applicable (The Incorporation of wholly owned subsidiary Company will be done as per the applicable laws in the Singapore)
6	Nature of consideration - whether cash consideration or share swap and details of the same	Cash.
7	Cost of subscription / price at which the shares are subscribed;	Price per Share: USD 1.00 Total investment amount upto USD 100.00 Mn.
8	Percentage of shareholding / control by the listed entity and / or number of shares allotted.]	100%

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com